NHS Blood & Transplant.
National Institute for Health Research Oxford Biomedical Research Centre.
Blood. 2020 Nov 12;136(20):2245-2246. doi: 10.1182/blood.2020008963.
In this issue of , Hueso et al report a study of COVID-19 convalescent plasma (CCP) in patients with COVID-19 and negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology with severe immunodeficiency due to prior treatment with anti-CD20 monoclonal antibodies. The study reports on the safety and efficacy of COVID-19 CCP in 17 patients with profound B-cell lymphopenia and protracted COVID-19 disease.
本期 杂志中，Hueso 等人报告了一项关于 COVID-19 恢复期血浆（CCP）治疗 COVID-19 且严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）血清学检测为阴性的严重免疫缺陷患者（既往接受过抗 CD20 单克隆抗体治疗）的研究。该研究报告了 17 例严重 B 细胞淋巴细胞减少和 COVID-19 疾病持续时间长的患者接受 COVID-19 CCP 的安全性和有效性。
